Kornimate/medical-research-clean huggingface dataset:
intravenous lidocaine to supress of cough reflex during anesthesia emergence

Conditions: Cough

Summary: introduction: although inflating tracheal cuff using lidocaine is effective for cough suppression, it may pressure tracheal cuff too much. intravenous continuous infusion of lidocaine has emerged recently for most general anesthesia in the context of opioid-sparing anesthesia for cancer, but the 95% effective dose (ed95) for cough suppression during anesthesia emergence is not determined yet. objective: the objectives of this study are to determine the ed95 of continuous infusion lidocaine for suppressing cough reflex during extubation by sex and age group.

ideal patient weight in kg will be considered. initial dose will be 0.5mg/kg.h and dose-change steps of 0.5mg/kg.h will occur depending on the incidence of emergence cough in the previous patient of the same group: * it will increase if coughed in a probability of 95% * it will decrease if not coughed in a probability of 5%. * it will remain the same otherwise. maximum dose will be 3mg/kg.h. all patients will receive remifentanil 0.025mcg/kg.min continuous infusion until extubation. patients groups will be determined by sex and age group (18-60 or \>60 years old), therefore, four independent groups will be studied: * female 18 to 60 years old * male 18 to 60 years old * female \> 60 years old * male \> 60 years old

Eligibility criteria:
inclusion criteria: * understands study risks and benefits, signs informed consent. * not pregnant. * not an airway surgery * no acute or chronic respiratory disease. * non smoker * no chronic cough exclusion criteria: * any protocol violation.

Keywords: general anesthesia cough anesthesia emergence lidocaine
nol index variations before and after a stellate ganglion block

Conditions: Chronic Pain Syndrome

Summary: to evaluate and compare the nol index variations after a painful physiotherapy exercise in patients with upper limb crps, before and after a stellate ganglion block.


Eligibility criteria:
inclusion criteria: * diagnosis of upper limb crps according to the budapest criteria12, for more than 6 months; * significant pain relief from stellate ganglion block; * undergoing physical therapy; * 18 years and older. exclusion criteria: * patients taking beta blockers * bilateral/generalized crps * patients needing sedation for the procedure * inability to understand a numeric pain rating scale due to cognitive dysfunction or linguistic barrier * movement disorder making a person unable to lie still for the duration of the evaluation period. * patient refusal
cognitive disorders in hereditary spastic paraplegia type 4

Conditions: Spastic Paraplegia

Summary: hereditary spastic paraplegia type 4 is the most frequent mutation of hereditary spastic paraplegias. it is commonly described as pure, with progressive weakness of the lower limbs, pyramidal syndrome and vesico-sphincter disorders. however, cognitive disorders have been reported for over 20 years, but remain poorly characterized.

our primary objective is to describe a pattern of cognitive impairment in hereditary spastic paraplegia type 4 using 18-fdg-pet metabolic imaging. as secondary objectives, we wish to study the presence of correlations between neuropsychological tests, clinical examination, 18-fdg-pet data and general and genetic data of the pathology. we also wish to investigate correlations between genotype and phenotype.

Eligibility criteria:
inclusion criteria: * patient over 18 years of age, living in the grand est region (france) * patient with a pathogenic or probably pathogenic variant (class 4 or 5) in the spast gene. exclusion criteria: * dementia comorbidities or cognitive disorders unrelated to the pathology that may affect neuropsychological tests.

Keywords: hereditary spastic paraplegia type 4 18-fdg-pet cognitive disorders
translating a dementia caregiver intervention into a mobile application

Conditions: Dementia; Alzheimer Disease; Caregiver Burnout

Summary: the overall goal of this development project is to combine elements of two efficacious interventions into a mobile health (mhealth) app for informal dementia caregivers. the investigators will conduct a 3-month feasibility trial of the newly-developed care-well app in 40 dementia caregivers to establish acceptability and feasibility of the intervention, study procedures, and outcome measures.

caring for a person with dementia is a highly stressful activity and is associated with negative physical and mental health consequences, including increased risk of depression and worse reported health-related quality of life. the proposed project aims to develop and translate an evidence-based, multi-component intervention into a mhealth app that has the potential to increase dementia caregivers' access to support and care. the investigators will conduct a feasibility trial, in which 40 dementia caregivers will be randomized to receive a computer tablet preloaded with the care-well app or preloaded with internet links relevant to dementia and caregiving. paper outcome measures will be assessed at baseline and end of intervention (3 months) during each study visit. to measure sustainability of the app, the first 10 caregivers from each group will be offered the tablets for an additional month to monitor usage of the app outside the formal trial. the goal of this aim is to determine feasibility of the intervention, study procedures, and outcome measures.

Eligibility criteria:
inclusion criteria: * adequate english-speaking and reading skills * provide at least 4 hours of supervision per day for the care recipient (either directly or by telephone) * live in the community (either with the care recipient or without) * have provided supervision/ assistance for at least 6 months prior to study enrollment and have no plans to place care recipient in long term care or to end their role as caregiver within 6 months of study enrollment. * report some degree of distress associated with caregiving * access to wifi at home exclusion criteria: * major acute medical illness * severe mental illness (e.g. bipolar, schizophrenia) * diagnosed cognitive impairment

Keywords: mobilehealth caregiving dementia alzheimer disease
diacerein on insulin secretion in diabetes

Conditions: Type 2 Diabetes Mellitus; Overweight; Obesity

Summary: aim. to assess the effect of interleukin 1β (il-1β) and tumor necrosis factor α (tnfα) inhibition with diacerein administration on insulin secretion and metabolic control of drug-naïve patients with type 2 diabetes mellitus (t2dm) and overweight or obesity. hypothesis. diacerein administration improves insulin secretion and metabolic control of drug-naïve patients with type 2 diabetes mellitus (t2dm) and overweight or obesity. materials and methods. design: randomized, double-blind, placebo-controlled clinical trial. population: 40 drug-naïve adult patients with t2dm and overweight or obesity. measurements: a metabolic profile including il-1β, tnfα, interleukin 6, and fasting insulin levels, as well as, hyperglycemic-hyperinsulinemic clamp technique; to assess the phases of insulin secretion and insulin sensitivity. intervention for 2 mo: diacerein (50 mg once daily) for the first 15 days and twice daily for 45 additional days or placebo. statistical analyses: wilcoxon signed rank and mann-whitney u test.


Eligibility criteria:
inclusion criteria: * fasting glucose levels between 7.0 and 11.1 mmol/l * a1c levels between 7 and 9% * same residential area and socioeconomic status * excessively sedentary or participated in heavy physical activity * nonsmokers * body weight was stable for at least 3 months before the study * blood pressure was \<130/80 mm hg exclusion criteria: * personal history of hepatic, renal or coronary artery disease * medications known to affect metabolism during the previous 6 months.

Keywords: type 2 diabetes mellitus overweight obesity
exploring hrv in antarctic overwintering members of asia

Conditions: Heart Rate Variability

Summary: extreme changes in the antarctic environment can cause emotional and autonomic dysfunction. in this study, volunteers from the antarctica stations in china provided scale scores and heart rate variability (hrv) data, which were used to assess the autonomic nervous system. enroll twenty-two members from zhongshan station and the great wall station who are overwintering. using the generalized anxiety disorder (gad-7) scale, the patient health questionnaire-9 (phq-9) scale, and the sf-36 quality of life scale to evaluate the individual's general physical and mental health. analyze hrv and other associated parameters.

this study was a prospective observational study. we selected 12 members in antarctica at the great wall station of the 37th chinese antarctic scientific expedition (csea) from march 2021 to april 2022. and 10 members in antarctica at zhongshan station in the 38th csea from december 2021 to april 2023. there were 22 members in total. team members are volunteers selected through interviews, followed by detailed medical and psychological examinations, and are made up of scientific and logistical staff. according to the different work content of the scientific expedition team members, and taking the average outdoor working time of 2 hours/day as the node, the scientific expedition team members are divided into outdoor groups (n=12) and indoor groups (n=10). participants will be assessed on the day they enter the antarctic station and leave. assessments include hrv, sf-36 quality of life questionnaire, patient health questionnaire-9 (phq-9) scale and generalized anxiety disorder (gad-7) scale. this study approved by the local ethics committee of shanghai tenth people's hospital, and conformed to the declaration of helsinki and its later amendments.

Eligibility criteria:
inclusion criteria: * team members are volunteers selected through interviews, followed by detailed medical and psychological examinations, and are made up of scientific and logistical staff. exclusion criteria: * people with physical or mental illness

Keywords: heart rate variability (hrv); antarctic regions; overwintering; physical harm; depression
pharmacokinetics, biodistribution, radiation dose and safety study of 68ga-nym005 in patients

Conditions: Clear Cell Renal Cell Carcinoma Metastatic

Summary: 68ga-nym005 is a caix-targeting small-molecular radiotracer for pet/ct imaging of clear cell renal cell carcinoma


Eligibility criteria:
inclusion criteria: 1. patients with pathologically confirmed metastatic renal clear cell carcinoma; 2. age range from 18 to 75 years old (including 18 and 75 years old); 3. ecog score of 0 or 1; 4. expected life \> 6 months; 5. gfr\> 60 ml/min; 6. women of childbearing age need to have a negative pregnancy test, and the subjects(including male subjects)agree to take effective contraceptive measures during the study period and for at least three months after the drug administration; 7. the subjects are able to maintain good communication with the researchers；understand and follow the requirements of this study and sign an informed consent form before the start of relevant research operations. exclusion criteria: 1. pregnant or lactating women, or women who plan to conceive during the study period or within three months after drug administration; 2. known or suspected to be allergic to the investigational drug or any of its components,acetazolamide or other sulfonamides: 3. accepting other investigational drugs upon enrollment, or within 5 biological half-lives of the drug at enrollment, or within 30 days after its last administration, whichever is longer; 4. those who have used any radioactive therapy medication within 90 days before investigational drug administration, or have received any radioactive diagnostic medication within 3 days before investigational drug administration; 5. on vegf tki treatment less than 7 days before 68ga-nym005 pet/ct, such as sunitinib,sorafenib, cabozantinib, pazopanib, or lenvatinib, a washout of one week before 68ga-nym005 pet/ct is required; 6. planned (for the period between injection of 68ga-nym005 and imaging) antineoplastic therapies; 7. plan to arrange surgery and other invasive interventions within 2 days after the injection of the investigational drug; 8. ongoing toxicity \>grade l from previous standard or investigational therapies； 9. patients with active infections during screening; 10. those who have no guarantee of being able to lie down quietly in the examination cabin during a pet examination, or those who suffer from claustrophobia and cannot cooperate in a pet examination: 11. other situations where the researchers believe that the subject is not suitable for inclusion in this study.
advanced mr imaging for early biologic tumor changes to neoadjuvant chemoradiation treatment for rectal cancer

Conditions: Rectal Cancer

Summary: the purpose of this study is to see whether three new types of mri techniques used during magnetic resonance imaging (mri) of the pelvis to look at rectal cancer can help doctors to tell if the tumor is getting better in response to the radiation and/or chemotherapy treatments.

this is a pilot study of dynamic contrast enhanced magnetic resonance imaging (dce-mri, aka perfusion mri) and diffusion-weighted mri (dwi-mri), herein referred to in combination as advanced mri (amri) in the investigation of early tumor response to standard multi-dose, fractionated external beam radiotherapy (ebrt) of the pelvis given in the neoadjuvant setting concurrent with chemotherapy as well as induction chemotherapy prior to chemoradiotherapy or consolidation chemotherapy after chemoradiotherapy for primary rectal adenocarcinoma. this protocol aims to expand upon the growing body of knowledge concerning early changes in tumor neovascularity and cellular density as a potential biomarker of therapy efficacy. it further aims to address the trend towards more refined treatment stratification for lower risk tumors to avoid morbidity from potentially unnecessary radiation, chemotherapy or even radical surgery, by assessing the earliest changes that occur in microvasculature and perfusion and diffusion of water during this treatment to see if these can be predictive of long-term efficacy of therapy.

Eligibility criteria:
inclusion criteria: * patients with primary locally advanced rectal adenocarcinoma (0-18cm from the anal verge) confirmed by mskcc pathologist and eligible to undergo chemoradiation and surgical resection at mskcc. * written informed consent * age equal to or greater than 21 years * willing and able to undergo all study procedures * patients must have a planned surgical resection of the rectum exclusion criteria: * patients younger than 21 years * pregnant and nursing women * contraindications for mri (such as claustrophobia, pacemaker, non mr-compatible artificial heart valves, cochlear implants, surgical clips in the brain, metal fragments in eye) * estimated gfr (using cockcroft formula appendix 2) less than 30 ml/min/1.73m2 (fda advises caution in using gadolinium-based contrast agents in patients with severe renal impairment). * history of allergic reaction to mr contrast media * inability to give informed consent in person

Keywords: mri rectum 13-019
ultrasound assessment of airway edema during laparoscopic cholecystectomy

Conditions: Airway Edema; Perioperative Complication; Pneumoperitoneum

Summary: this prospective, double-blind, randomized clinical trial aims to investigate the development of airway edema associated with intra-abdominal pressure during laparoscopic cholecystectomy. a total of 66 adult patients undergoing elective laparoscopic cholecystectomy under general anesthesia will be randomly assigned into two equal groups (33 patients per group) based on intra-abdominal pressure levels: low-pressure and standard-pressure pneumoperitoneum. ultrasonographic measurements will be used to assess airway soft tissue thickness at predefined time points before and after the pneumoperitoneum. the primary objective is to determine whether increased intra-abdominal pressure contributes to postoperative airway edema, which may pose a risk during extubation.

airway edema can lead to difficult extubation and perioperative complications. pneumoperitoneum during laparoscopic surgery increases intra-abdominal pressure (iap), which may contribute to airway soft tissue edema due to cephalad fluid shifts and venous congestion. this prospective, randomized, double-blind study aims to assess whether different levels of iap have a measurable effect on airway soft tissue thickness. patients aged 18 to 65 years, classified as asa i-ii, and scheduled for elective laparoscopic cholecystectomy will be included in the study. upon arrival in the operating room, standard monitoring will be applied, anesthesia will be induced using intravenous sedation, and endotracheal intubation will be performed. in the preoperative period, airway ultrasonography will be used to measure tongue thickness, midsagittal tongue cross-sectional area, tongue width, lateral pharyngeal wall thickness, parapharyngeal area thickness, and submental area thickness. patients will be randomly assigned into two groups: group 1: patients receiving 10 mmhg intra-abdominal pressure group 2: patients receiving 14 mmhg intra-abdominal pressure t0: before intubation t1: after intubation t2: 30 minutes after the initiation of pneumoperitoneum t3: 5 minutes after extubation t4: 1 hour after extubation t5: 2 hours after extubation

Eligibility criteria:
inclusion criteria: * age between 18 and 65 years * asa physical status i-ii * body mass index (bmi) \< 30 kg/m² * mallampati score i-ii * scheduled for elective laparoscopic cholecystectomy exclusion criteria: * history of difficult intubation * upper respiratory tract infection * obstructive sleep apnea or stop-bang score ≥3 * severe cardiopulmonary disease * pregnancy * indication for emergency surgery

Keywords: airway ultrasound upper airway edema pneumoperitoneum intra-abdominal pressure
enhanced recovery after biliary tract surgery

Conditions: Biliary Stricture; Cholangiocarcinoma; Cholangitis; Choledocholithiasis

Summary: the aim of the study is to improve the immediate results after reconstructive and restorative operations on the biliary tract by substantiating the management of the perioperative period on the principles of "enhanced recovery after surgery".

a prospective randomized study on the effect of fast-track surgery on the immediate postoperative results after various reconstructive and restorative operations on the bile ducts. in the department of surgical hepatology and transplantation, a prospective randomized study will include patients (about 50) with planned reconstructive and restorative operations on the bile ducts for malignant and benign diseases of the bile ducts.

Eligibility criteria:
inclusion criteria: 1. patients with malignant diseases of the biliary tract (cholangiocarcinoma): 1.1. tumor resectability 1.2. absence: * distant metastases * carcinomatosis * perforation of the tumor and peritonitis * sprouting into adjacent organs and tissues (locally advanced cancer) * total adhesion process in the abdominal cavity (after previous operations). 1.3. planned reconstructive surgery on the biliary tract. 2. patients with benign biliary tract pathology. 2.1. planned reconstructive or restorative surgery on the biliary tract for the following diseases: * choledocholithiasis * mirizzi syndrome * cysts of the common bile duct * strictures of the common bile duct * injuries to the bile ducts * adenoma and stricture of the obd exclusion criteria: 1. scale asa\> iii (severe concomitant cardiovascular pathology). 2. palliative reconstructive surgery. 3. previously performed operations on the bile ducts (up to 1 month). 4. cachexia.

Keywords: fast track, enhanced recovery after surgery, biliary surgery
patakess protocol : clinical and biological analysis of exocrine pancreatic tumors

Conditions: Exocrine Pancreatic Cancer

Summary: patakess is a monocentric non interventional cohort study (prospective (alive patients) and retrospective (dead patients with biological material from surgery and/or biopsies already collected)). patakess consists of clinical and biological analyses of exocrine pancreatic tumors. data are derived from tumor samples taken for routine health care purposes in patients managed at centre léon bérard (lyon-france) since january 2010. the main objective is to determine correlation between biological and clinical characterizations of patients suffering from exocrine pancreatic tumor.

pancreatic adenocarcinoma cancer is an aggressive cancer which represents 95% of pancreatic cancer. pancreatic adenocarcinoma cancer is one of the deadliest cancers (5th cause of death per cancer) ; it has a very poor prognosis: 5-year survival (regardless of all stades at diagnosis). pancreatic adenocarcinoma cancer is characterized by early metastasis. therefore, development of efficient systemic therapeutics is one of the keys to improving prognosis. newly developed immune check-point inhibitors seem to have limited efficacy in pancreatic adenocarcinoma except for msi-h (microsatellite instability-high) or dmmr (mismatch repair deficient)/msi-h tumors. however, recent data suggest that immune surveillance could control metastatic dissemination of pancreatic adenocarcinoma cancer. several studies showed strong interactions between pancreatic tumor cells and tumor stroma in metastatic dissemination and in resistance to conventional therapeutics. many data about pancreatic primitive tumors from murine animals models are available ; however few data on tumor stroma and its interactions with tumor cells of metastasis from adenocarcinoma pancreas are available. few data on correlation between molecular alterations types (mutations, deletions, amplifications) in pancreatic adenocarcinoma cells and tumor stroma characteristics (primitive and metastatic stroma (cells composition, immune infiltration)) are also available. in patakess study, clinical and biological data are derived from tumor samples taken for routine health care purposes in patients managed at centre léon bérard (lyon-france) since january 2010.

Eligibility criteria:
inclusion criteria: * male or female patient 18 age or older * patient operated on for exocrine pancreatic adenocarcinoma at centre léon bérard since 01/01/2010. * histological diagnosis of exocrine pancreatic adenocarcinoma confirmed with surgery specimen. exclusion criteria: * not applicable

Keywords: pancreatic cancer immune infiltrate molecular alterations tumor stroma